SOCIETAL IMPACT ASSESSMENT OF OFATUMUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A 5-PILLAR ANALYSIS FROM A SOCIETAL PERSPECTIVE
Author(s)
Omar Maoujoud, MD, PhD1, sanaa haouraji, Msc2;
1Resarch team of Pharmacoeconomics & Pharmacoepidemiology, Moroccan Society of healt economics (SMEPS), Facuty of Medicine, Mohamed V university Rbat Morocco, Rabat, Morocco, 2EOS Executive Lab, Casablanca, Morocco
1Resarch team of Pharmacoeconomics & Pharmacoepidemiology, Moroccan Society of healt economics (SMEPS), Facuty of Medicine, Mohamed V university Rbat Morocco, Rabat, Morocco, 2EOS Executive Lab, Casablanca, Morocco
OBJECTIVES: To quantify the societal value of ofatumumab (Bonspri®) versus standard-of-care disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) using a societal impact assessment framework from the Moroccan perspective over a 5-year horizon (2026-2030)
METHODS: A 5-pillar societal impact model was developed incorporating: (P1) preserved market productivity based on EDSS progression gradients (-7% employment/EDSS point); (P2) preserved domestic productivity; (P3) informal caregiver savings; (P4) direct medical cost savings from avoided relapses; and (P5) indirect economic effects via input-output multiplier (1.80). Clinical inputs derived from ASCLEPIOS I/II trials (ARR 0.11 vs 0.22; HR progression 0.66). Economic parameters sourced from Morocco's High Commission for Planning (average salary: 62,256 MAD; weighted LFPR: 34.1%). Population projections aligned with a validated Budget Impact Analysis (n=2,182 eligible patients; market share plateau 25.6% by Year 5). Outcomes were discounted at 3.5% annually. One-way sensitivity analysis (OWSA) and multivariate scenario analyses assessed robustness
RESULTS: Over 5 years (1,847 discounted patient-years), ofatumumab generated a total societal impact of 10.88 million MAD (€1.01M), representing 35.7% of net budget impact. Per patient-year societal value was 5,892 MAD. Pillar contributions were: P4 (avoided medical costs) 45.5% (4.95M MAD, 571 relapses avoided); P5 (indirect effects) 24.2%; P1 (market productivity) 11.8%; P3 (caregiver savings) 9.5%; P2 (domestic productivity) 9.0%. OWSA identified EDSS gain (amplitude: 5.4M MAD), I-O multiplier, and relapse cost as most influential parameters. Scenario analysis demonstrated consistent positive impact: pessimistic 7.05M, base case 10.88M, optimistic 16.06M MAD
CONCLUSIONS: Ofatumumab demonstrates substantial societal value in Morocco, with over one-third of pharmaceutical investment recovered through productivity preservation, healthcare savings, and economic spillovers. This framework provides comprehensive assessment complementing traditional cost-effectiveness analyses for market access decisions in emerging markets
METHODS: A 5-pillar societal impact model was developed incorporating: (P1) preserved market productivity based on EDSS progression gradients (-7% employment/EDSS point); (P2) preserved domestic productivity; (P3) informal caregiver savings; (P4) direct medical cost savings from avoided relapses; and (P5) indirect economic effects via input-output multiplier (1.80). Clinical inputs derived from ASCLEPIOS I/II trials (ARR 0.11 vs 0.22; HR progression 0.66). Economic parameters sourced from Morocco's High Commission for Planning (average salary: 62,256 MAD; weighted LFPR: 34.1%). Population projections aligned with a validated Budget Impact Analysis (n=2,182 eligible patients; market share plateau 25.6% by Year 5). Outcomes were discounted at 3.5% annually. One-way sensitivity analysis (OWSA) and multivariate scenario analyses assessed robustness
RESULTS: Over 5 years (1,847 discounted patient-years), ofatumumab generated a total societal impact of 10.88 million MAD (€1.01M), representing 35.7% of net budget impact. Per patient-year societal value was 5,892 MAD. Pillar contributions were: P4 (avoided medical costs) 45.5% (4.95M MAD, 571 relapses avoided); P5 (indirect effects) 24.2%; P1 (market productivity) 11.8%; P3 (caregiver savings) 9.5%; P2 (domestic productivity) 9.0%. OWSA identified EDSS gain (amplitude: 5.4M MAD), I-O multiplier, and relapse cost as most influential parameters. Scenario analysis demonstrated consistent positive impact: pessimistic 7.05M, base case 10.88M, optimistic 16.06M MAD
CONCLUSIONS: Ofatumumab demonstrates substantial societal value in Morocco, with over one-third of pharmaceutical investment recovered through productivity preservation, healthcare savings, and economic spillovers. This framework provides comprehensive assessment complementing traditional cost-effectiveness analyses for market access decisions in emerging markets
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE137
Topic
Economic Evaluation
Topic Subcategory
Novel & Social Elements of Value
Disease
SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), SDC: Neurological Disorders